Zheng Cui
Union Hospital
Wuhan, 430022, China
Wuhan, 430022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring.
Journal: Drug design, development and therapy
Published: March 26, 2026
Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.
Journal: BMC cancer
Published: October 09, 2025
Safety and Efficacy of Flumatinib in Patients with Chronic Phase Chronic Myeloid Leukemia: A Real-Life Cohort Observational Study.
Journal: Blood and lymphatic cancer : targets and therapy
Published: October 09, 2025
Impact of additional cytogenetic aberrations at diagnosis of chronic phase chronic myeloid leukemia.
Impact of additional cytogenetic aberrations at diagnosis of chronic phase chronic myeloid leukemia.
Journal: Therapeutic advances in medical oncology
Published: May 22, 2025
Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia.
Journal: Drug design, development and therapy
Published: February 07, 2025
Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China.
Journal: Therapeutic advances in hematology
Published: February 19, 2024
Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Journal: International immunopharmacology
Published: January 28, 2024
Intestinal lymphatic transport of Smilax china L. pectic polysaccharide via Peyer's patches and its uptake and transport mechanisms in mononuclear phagocytes.
Journal: Carbohydrate polymers
Published: January 13, 2024
Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia.
Journal: International immunopharmacology
Published: May 01, 2023
Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China.
Journal: Frontiers in oncology
Published: February 28, 2023
Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings.
Journal: Frontiers in oncology
Published: February 04, 2023
Reply to "Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!"
Journal: Cancer
Published: December 08, 2022
Last Updated: 09/26/2026